The current consensus that inflammatory responses, TNFA signaling, and IFN signaling correlate with immunotherapy in cancer and patient response implies that the potential immunotherapeutic value of IFI30 could be explored through these pathways, which also substantiates our previous hypothesis (35–37). The gene discussed is IFNA1; the disease is cancer.